|
Endo International plc is global specialty healthcare company. It was created as a result of a management buyout from DuPont Merck in 1997. Three DuPont Merck executives (Carol A. Ammon, Chairman, President & CEO, and Mariann T. MacDonald, Executive Vice President, Operations, along with another colleague) purchased all of Endo Laboratories L.L.C.'s generic products along with 12 important brand products, including Percocet, Percodan, and Opana. The new company was called "Endo Pharmaceuticals Inc." Endo acquired Algos Pharmaceutical Corporation through a merger in July 2000 and began to trade publicly (). Endo successfully completed a secondary offering for a total of 12,925,000 shares of its common stock in Oct 2001. The net proceeds were used to pay existing bank debt. On February 28, 2014, Endo completed its acquisition of Paladin Labs, a leading Canada-based specialty pharmaceutical company. Endo and Paladin Labs came together under Endo International plc and Endo established new global headquarters in Dublin, Ireland. Endo develops, manufactures, markets and distributes quality branded pharmaceutical, generic and device products though its operating companies. The company has global headquarters in Dublin, Ireland and U.S. headquarters in Malvern, PA. ==Corporate governance== , Endo's chief executive officer (CEO) was Rajiv De Silva. , Endo's chief financial officer (CFO) was Suketu Upadhyay. A prior CFO, Charles A. Rowland Jr., had been appointed in December 2006.〔 抄文引用元・出典: フリー百科事典『 ウィキペディア（Wikipedia）』 ■ウィキペディアで「Endo International」の詳細全文を読む スポンサード リンク
|